Uncategorized Archives - Page 34 of 87 - PsychedelicNewsWire (PNW)

ThursdayJun 10, 2021 10:45 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at H.C. Wainwright’s Upcoming Virtual Psychedelics Conference

Tryp Therapeutics’ Chairman and CEO Greg McKee will present at the virtual Psychedelics in Psychiatry and Beyond Conference planned for Thursday, June 17, 2021 As part of his presentation, McKee will discuss Tryp’s business and its pipeline, which includes its proprietary psilocybin-centered drug development program Tryp will present alongside other pharmaceutical companies leading research in psychedelic-assisted therapeutics Psychedelics have increasingly drawn the attention of different players and companies thanks to the research-driven revelations regarding their utility in treating a wide range of neuropsychiatric diseases. As a pharmaceutical company that has been furthering such research – specifically on psilocybin, a psychedelic…

ThursdayJun 10, 2021 10:30 am

Therapeutic Psychedelics Could Be Worth at Least $6.5 Billion by 2030

A recently released report forecasts that by 2030, the psychedelics therapeutics market may be worth more than $6 billion. The annualized rate of growth is predicted to be almost 15%. A lot of research on psychedelics has been conducted in the recent past, with a growing body of evidence suggesting that administering psychedelic substances such as LSD and psilocybin, combined with psychotherapy, may help manage the symptoms of various mental health conditions (i.e., substance use disorders and depression). To date, almost 150 types of psychedelic substances that may be used as therapeutics have been identified. These psychedelics have shown that…

WednesdayJun 09, 2021 3:00 pm

Study Finds Americans Are Receptive to Psychedelic Treatments

The coronavirus pandemic has not only affected the economies of different countries as well as industries around the world, but it has also affected the mental and emotional health of millions of individuals globally. Field Trip Health, one of the biggest providers of psychedelic therapies globally, recently conducted a survey in the United States focused on both emotional and mental health. The company’s aim was to find out how open-minded respondents were towards including psychedelics into their treatment plans. The survey’s results report that more than 8 out of every 10 individuals who responded experienced at least one symptom of…

WednesdayJun 09, 2021 9:15 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files International Patent to Protect Potential Patient Coverage in 153 Countries

Cybin submits first-ever Patent Cooperation Treaty (“PCT”) filing By filing a single PCT application, the company simultaneously seeks protection for its proprietary drug treatments in a large number of countries Cybin filed the PCT application to provide broad international patent protection of key intellectual property Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, continues to focus on its goal to improve the lives of those suffering from mental illness by changing the expectation of treatment. As part of that mission, the company has filed an international patent application that would provide the potential to obtain patent…

WednesdayJun 09, 2021 9:00 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Inks White Label Agreement as Strategic Planning Pays Off

White label agreement with FLO Brands outlines launch of cannabis vape product line PULL beginning to execute strategy to get white label products into provincial dispensaries, drive up to $3 million of annual revenue Nikolaevsky reports that “white labeling has also begun to build momentum and gain sales traction for us” Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic industry, announced that it has finalized a white label agreement to launch a line of cannabis vape products (https://ibn.fm/MfSkc). The agreement was made between Pure…

TuesdayJun 08, 2021 1:30 pm

Study Links Hallucinogen Use to Emotional Dysregulation, Risk Taking Among Youth

Unlike other hard drugs, hallucinogens such as LSD are seen as less likely to give rise to physical dependence and as less harmful. However, they are hardly safe, and sometimes their use is followed by unpredictable and intense psychological dependency, flashbacks and cognitive impairment. A lot of research has been done to investigate the relationship between the use of hallucinogens and personality. However, few studies have examined traits such as emotion dysregulation, sensation and risk seeking and impulsivity, which are all taken into account when studying other hard drugs. In an attempt to fill this research gap, a group of…

MondayJun 07, 2021 2:30 pm

Report Suggests That Use of Psychedelics May Improve Color Blindness

A recent study conducted proposes that psychedelic substances may reduce color blindness symptoms. The findings, which were reported in “Drug Sciences, Policy and Law,” discuss more than 20 anecdotal reports that describe how color blindness was improved after participants ingested drugs such as psilocybin and LSD. Historical and anecdotal reports have maintained for a while that psychedelic substances could adjust color vision. The researchers who conducted the study note that hurdles to carrying out more research on psychedelics have impeded further research on this. In prior studies, JEC Anthony and his colleagues accepted submissions from individuals who recorded changes in…

FridayJun 04, 2021 1:00 pm

Study Discovers Psilocybin May Have Lasting Benefits for Migraines

Researchers have been studying psilocybin in an attempt to discover any benefits the substance holds that may be useful to migraine sufferers. Psilocybin is found in magic mushrooms and is the main active ingredient responsible for the psychedelic effects mushrooms produce. The findings, which were reported in “Neurotherapeutics,” offer evidence that psilocybin may provide long-lasting therapeutic benefits to individuals who suffer from migraines. Over the years, anecdotal reports have claimed that psilocybin may lessen the symptoms of migraines. However, there hasn’t been enough scientific evidence to support these reports. This recently published study is the first placebo-controlled, double-blind study that…

FridayJun 04, 2021 9:30 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Opens Direct-To-Consumer Amazon Store under Pure Mushrooms Brand

PULL subsidiary Pure Mushrooms Corp. opens direct-to-consumer e-Commerce store on Amazon platform Store features Reishi, Maitake formulations with plans to add Lion’s Mane in summer 2021 Global functional mushroom market valued at $25.4 billion in 2020, expected CAGR of 8.44% from 2021-2026 Company expands psychedelic vertical through letter of intent with Psyence Group to co-produce psychedelic mushroom-based psilocybin formulations Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, recently announced that Pure Mushrooms Corp., its wholly owned subsidiary, has opened a direct-to-consumer, e-Commerce store…

ThursdayJun 03, 2021 3:00 pm

Deepak Chopra Plans to Raise Awareness About Healing Potential of Psychedelics

Last week, Deepak Chopra revealed that he’d entered into a new partnership with MindMed (NEO: MMED) (OTCQB: MMEDF), which aligned with his continued interest in mind-body healing. MindMed is a clinical-stage biotech company that is researching psychedelic medicine. In his statement, the self-care leader announced that the collaboration was for the public awareness of psychedelic research and public education, adding that while he didn’t believe psychedelics were a universal cure, they had a huge role to play in suicide prevention and the treatment of depression and post-traumatic stress disorder, among other conditions. A phase 3 clinical trial conducted by MindMed…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized